Barbara Yanni
Director/Board Member bei TREVENA, INC.
Vermögen: 131 558 $ am 31.03.2024
Profil
Barbara Yanni is currently serving as an Independent Director in four firms, namely Vaccinex, Inc., Pharming Group NV, Trevena, Inc., and Mesentech, Inc. She previously served as a Director in Symic Bio, Inc. and Symic Holdings LLC from 2015 to 2019.
She was also an Independent Director in ABIONYX Pharma SA from 2018 to 2020 and in Akcea Therapeutics, Inc. from 2019 to 2020.
Additionally, she is currently serving as an Independent Director in Oncorus, Inc. from 2021 to 2023.
Prior to these roles, she was the Chief Licensing Officer & Vice President at Merck & Co., Inc. from 2001 to 2014.
Ms. Yanni completed her undergraduate degree from Wellesley College and her graduate degrees from New York University and Stanford Law School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
PHARMING GROUP NV
0,02% | 31.03.2024 | 119 542 ( 0,02% ) | 131 558 $ | 31.03.2024 |
TREVENA, INC.
-.--% | 09.02.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
VACCINEX, INC.
-.--% | 22.03.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
ONCORUS, INC.
-.--% | 31.03.2023 | 0 ( -.--% ) | - $ | 31.12.2023 |
Aktive Positionen von Barbara Yanni
| Unternehmen | Position | Beginn |
|---|---|---|
| TREVENA, INC. | Director/Board Member | 01.07.2014 |
| VACCINEXPAR | Director/Board Member | 01.02.2015 |
| PHARMING GROUP N.V. | Director/Board Member | 11.12.2020 |
Mesentech, Inc.
 Mesentech, Inc. BiotechnologyHealth Technology Mesentech, Inc. engages in the development of drug conjugate that delivers medicines selectively to the bone. Its bone anabolic drug conjugates are used as a treatment for renal osteodystrophy, osteogenesis imperfecta, and Duchenne associated osteoporosis. The company was founded by Robert Young, Ian McBeath, Michael Underhill, Pieter R. Cullis, and Fabio Rossi and is headquartered in Vancouver, Canada. | Director/Board Member | 01.11.2020 |
Ehemalige bekannte Positionen von Barbara Yanni
| Unternehmen | Position | Ende |
|---|---|---|
| ONCORUS, INC. | Director/Board Member | 27.07.2023 |
| AKCEA THERAPEUTICS, INC. | Director/Board Member | 12.10.2020 |
| ABIONYX PHARMA | Director/Board Member | 01.01.2020 |
Symic Bio, Inc.
 Symic Bio, Inc. BiotechnologyHealth Technology Symic Bio, Inc. develops new category of therapeutics. The company studies treatments for osteoarthritis and cardiovascular ailments. The firm developed a new therapeutic category of bioconjugates that directly target the extracellular matrix, the biologically active environment which plays critical roles for cell proliferation, migration, differentiation and survival. The company was founded by Kate Stuart and John Paderi in 2012 and is headquartered in San Francisco, CA. | Director/Board Member | 01.08.2019 |
Symic Holdings LLC
 Symic Holdings LLC BiotechnologyHealth Technology Symic Holdings LLC develops new category of therapeutics. The company was founded by John Paderi, Kate Stuart and Alyssa Panitch and is headquartered in Emeryville, CA. | Director/Board Member | 01.01.2019 |
Ausbildung von Barbara Yanni
| New York University | Graduate Degree |
| Wellesley College | Undergraduate Degree |
| Stanford Law School | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 6 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| VACCINEXPAR | Health Technology |
| PHARMING GROUP N.V. | Health Technology |
| ABIONYX PHARMA | Health Technology |
| TREVENA, INC. | Health Technology |
| ONCORUS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Symic Bio, Inc.
Symic Bio, Inc. BiotechnologyHealth Technology Symic Bio, Inc. develops new category of therapeutics. The company studies treatments for osteoarthritis and cardiovascular ailments. The firm developed a new therapeutic category of bioconjugates that directly target the extracellular matrix, the biologically active environment which plays critical roles for cell proliferation, migration, differentiation and survival. The company was founded by Kate Stuart and John Paderi in 2012 and is headquartered in San Francisco, CA. | Health Technology |
Symic Holdings LLC
Symic Holdings LLC BiotechnologyHealth Technology Symic Holdings LLC develops new category of therapeutics. The company was founded by John Paderi, Kate Stuart and Alyssa Panitch and is headquartered in Emeryville, CA. | Health Technology |
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA. | Health Technology |
Mesentech, Inc.
Mesentech, Inc. BiotechnologyHealth Technology Mesentech, Inc. engages in the development of drug conjugate that delivers medicines selectively to the bone. Its bone anabolic drug conjugates are used as a treatment for renal osteodystrophy, osteogenesis imperfecta, and Duchenne associated osteoporosis. The company was founded by Robert Young, Ian McBeath, Michael Underhill, Pieter R. Cullis, and Fabio Rossi and is headquartered in Vancouver, Canada. | Health Technology |
